Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but highlighted a strategic shift toward liquidation through a merger. Net loss was $7.8M vs. $8.7M expected, while GAAP EPS of -$2.44 beat the -$2.65 mean estimate due to aggressive cost-cutting and a $1.9M gain on lease terminations. Revenue remained at $0 as expected following the wind-down of all gene therapy programs. Cash reserves of $24.2M triggered a going concern warning, as the company prepares to close its merger with Remix Therapeutics in Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Passage Bio(PASG) the EBIT is -8.272 M (+19.95%), Beat estimate;the EPS is -2.44 (+17.57%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B19.95%
-0.01B6.81%
+0.00B13.14%
EPSExceed expectations
-2.4417.57%
-2.646710.59%
+0.20676.98%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf